FLOW CYTOMETRY, CD 38

The Flow Cytometry CD38 Test is a specialized immunophenotyping assay used to detect and measure the expression of CD38, a transmembrane glycoprotein found on various immune cells, including plasma cells, activated lymphocytes, and hematopoietic precursor cells. CD38 is one of the most important markers used in hematology for identifying plasma cells and evaluating hematological malignancies.

Flow cytometry technology enables rapid and accurate analysis of thousands of cells individually, helping identify CD38-positive cell populations and assess their characteristics. CD38 is commonly included in comprehensive immunophenotyping panels used for diagnosing and monitoring Multiple Myeloma, plasma cell neoplasms, leukemias, lymphomas, and other blood disorders.

In plasma cell disorders, CD38 is strongly expressed on plasma cells and is frequently evaluated together with CD138 and other markers to distinguish normal plasma cells from abnormal or malignant plasma cell populations. The test also contributes valuable information in leukemia and lymphoma classification.

Benefits of the Test

• Identifies plasma cell populations
• Assists in diagnosing Multiple Myeloma
• Supports leukemia and lymphoma immunophenotyping
• Helps classify hematological malignancies
• Assists disease monitoring and follow-up
• Provides important diagnostic and prognostic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD38 testing for:

• Suspected Multiple Myeloma
• Plasma cell disorder evaluation
• Monoclonal gammopathy assessment
• Leukemia investigation
• Lymphoma evaluation
• Bone marrow disorder assessment
• Monitoring treatment response
• Comprehensive hematological immunophenotyping

The test helps characterize abnormal plasma cell and lymphoid populations and supports accurate diagnosis.

Preparation Before Test

The test may require:

• Bone marrow aspirate
• Peripheral blood sample
• Body fluid specimen
• Other clinically relevant samples

Preparation generally includes:

• No fasting is required
• Inform your physician about current medications and treatments
• Follow laboratory collection instructions

The specimen is processed using advanced multiparameter flow cytometry systems.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on panel complexity and laboratory workflow.

Who Should Take This Test?

• Patients with suspected Multiple Myeloma
• Individuals with abnormal serum protein studies
• Patients with leukemia or lymphoma
• Individuals undergoing bone marrow evaluation
• Patients with plasma cell disorders
• Individuals referred by hematologists or oncologists

Flow Cytometry CD38 testing is an important component of modern hematology diagnostics and plasma cell evaluation.

Clinical Significance

CD38 expression may be observed in:

• Normal Plasma Cells
• Multiple Myeloma
• Plasma Cell Leukemia
• Monoclonal Gammopathy of Undetermined Significance (MGUS)
• Acute Leukemias
• Chronic Lymphocytic Leukemia (CLL)
• Various Lymphomas
• Activated Immune Cells

Strong CD38 expression on plasma cells is particularly important in identifying plasma cell neoplasms and monitoring disease progression.

Important Note

CD38 is usually interpreted together with markers such as CD138, CD19, CD45, CD56, CD117, CD20, Kappa Light Chains, and Lambda Light Chains. Accurate diagnosis requires comprehensive interpretation by a hematopathologist along with bone marrow findings, serum protein studies, and clinical information.